Jia Z X, Jiang C, Lu S X, Liu J P, Guo X Y, Li S N, Liu N, Jiang C X, Sang C H, Tang R B, Long D Y, Yu R H, Bai R, Wu J H, Du X, Dong J Z, Ma C S
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University; National Clinical Research Center for Cardiovascular Diseases, Beijing 100029, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2019 Aug 24;47(8):595-601. doi: 10.3760/cma.j.issn.0253-3758.2019.08.002.
This study explored the relationship between weight control and atrial fibrillation (AF) recurrence after catheter ablation in overweight and obese patients. We prospectively enrolled consecutive 333 overweight and obese patients aged 28 to 87 years old, who underwent catheter ablation for AF in Beijing Anzhen Hospital between October 2015 and February 2016. Data of patients' characteristics, laboratory examination and treatment were collected at baseline. Each patient was followed up at 3, 6 and 12 months after ablation to collect information on weight, AF recurrence, stroke, major bleeding, hospitalization for cardiovascular reasons and death, etc. Patients were divided into weight controlled group (ΔBMI<-1 kg/m(2)) and weight uncontrolled group (ΔBMI≥-1 kg/m(2)), according to the changes in the most recent exposure BMI before AF recurrence in patients with recurrence or the BMI at 12 months' follow-up in patients without recurrence and the BMI at baseline. Multivariate logistic regression was performed to adjust other known risk factors of AF recurrence and to explore the association between weight control and AF recurrence after catheter ablation. There were 54 patients in weight controlled group and 279 patients in weight uncontrolled group. There were no significant differences in age, gender, education level, left atrial size and history of hypertension between the two groups (all 0.05). The proportion of patients using angiotensin-converting enzyme inhibitors/angiotensin receptor blockers was higher in the weight controlled group (50.0%(27/54) vs. 34.8%(97/279), 0.034). However, there was no significant difference in the proportion of patients with obesity (33.3% (18/54) vs. 29.7% (83/279)), paroxysmal AF (59.3% (32/54) vs. 56.6% (158/279)) and AF duration less than 5 years (76.9% (40/52) vs. 65.4% (178/272)) between the weight controlled group and the uncontrolled group. During 1-year follow-up after ablation, the recurrence rate of AF was significantly lower in the weight controlled group than that in the weight uncontrolled group (14.8% (8/54) vs. 32.6%(91/279), 0.009). Multivariable logistic regression analysis shows that weight control is independently associated with a lower postoperative AF recurrence rate (0.40, 95 0.18-0.90, 0.026). Weight control is strongly associated with a lower AF recurrence rate after catheter ablation in overweight and obese patients.
本研究探讨了超重和肥胖患者体重控制与导管消融术后房颤(AF)复发之间的关系。我们前瞻性地纳入了2015年10月至2016年2月在北京安贞医院接受AF导管消融术的连续333例年龄在28至87岁的超重和肥胖患者。在基线时收集患者的特征、实验室检查和治疗数据。在消融术后3、6和12个月对每位患者进行随访,以收集体重、AF复发、中风、大出血、心血管原因住院和死亡等信息。根据复发患者AF复发前最近一次暴露BMI的变化或未复发患者12个月随访时的BMI以及基线时的BMI,将患者分为体重控制组(ΔBMI<-1 kg/m²)和体重未控制组(ΔBMI≥-1 kg/m²)。进行多因素逻辑回归以调整AF复发的其他已知危险因素,并探讨体重控制与导管消融术后AF复发之间的关联。体重控制组有54例患者,体重未控制组有279例患者。两组在年龄、性别、教育水平、左心房大小和高血压病史方面无显著差异(均P>0.05)。体重控制组使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂的患者比例较高(50.0%(27/54)对34.8%(97/279),P=0.034)。然而,体重控制组和未控制组在肥胖患者比例(33.3%(18/54)对29.7%(83/279))、阵发性AF比例(59.3%(32/54)对56.6%(158/279))和AF持续时间小于5年的患者比例(76.9%(40/52)对65.4%(178/272))方面无显著差异。在消融术后1年的随访期间,体重控制组的AF复发率显著低于体重未控制组(14.8%(8/54)对32.6%(91/279),P=0.009)。多变量逻辑回归分析表明,体重控制与较低的术后AF复发率独立相关(OR=0.40,95%CI 0.18-0.90,P=0.026)。体重控制与超重和肥胖患者导管消融术后较低的AF复发率密切相关。